Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Open accessAbstract
Background: It has been reported that the occurrence of immune-related adverse events (irAEs) in oncological patients treated with immune-checkpoint inhibitors (ICIs) may be associated with favorable clinical outcome. We reported the clinical correlation between irAEs and the efficacy of ICIs in a real-world cohort of metastatic renal cell cancer (mRCC) patients. Methods: We retrospectively evaluated 43 patients with mRCC who were treated with nivolumab or with nivolumab plus ipilimumab. We considered seven specific classes of irAEs including pulmonary, hepatic, gastrointestinal, cutaneous, endocrine, rheumatological, and renal manifestations. We assessed progression-free survival (PFS) of specific irAEs classes compared to the no-irAEs group. Results: Twenty-nine out of 43 patients (67.4%) experienced a total of 49 irAEs registered. The most frequent irAE was thyroid dysfunction (n = 14). The median PFS after the beginning of therapy was significantly longer in patients with thyroid dysfunction and cutaneous reactions. In multivariate analysis, thyroid dysfunction was an independent factor for favorable outcome [HR: 0.29 (95% CI 0.11–0.77) p = 0.013]. Moreover, experiencing ≥2 irAEs in the same patient correlated in multivariate analysis with better outcome compared with none/one irAE [HR: 0.33 (95% CI 0.13–0.84) p = 0.020]. Conclusions: This retrospective study suggests an association between specific irAES (thyroid dysfunction and skin reaction) and efficacy of ICIs in metastatic RCC. Notably, multiple irAEs in a single patient were associated with better tumor response.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Despite immune-related adverse events, nivolumab proved to have a favorable safety profile in patients with metastatic renal cell cancer.
“Despite the presence of immune-related adverse events (irAE) such as renal, gastrointestinal, pulmonary, hepatic, cutaneous, rheumatological, and endocrine manifestations in patients with metastatic renal cell cancer, nivolumab proved to have a favorable safety profile [38].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · see citing works
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · see citing works
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J. B. A. G., Rini, B. I., Albiges, L. K., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Négrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,512 · see citing works
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · see citing works
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,287 · see citing works
Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,279 · see citing works
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003 · see citing works
Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 937 · see citing works
Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923 · see citing works
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863 · see citing works
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625 · see citing works
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 618 · see citing works
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 546 · see citing works
Hussaini, S. M. Q., Chehade, R., Boldt, G., Raphael, J., Blanchette, P., Vareki, S. M., & Fernandes, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102134 · Cited by 397 · see citing works
Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377 · see citing works
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 357 · see citing works
Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G., Brambilla, M., Baglivo, S., Grossi, F., & Chiari, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2805-3 · Cited by 345 · see citing works
Liu, L., Bai, X., Wang, J., Tang, X.-R., Wu, D., Du, S., Du, X., Zhang, Y., Zhu, H., Fang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0558 · Cited by 322 · see citing works
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 245 · see citing works
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 237 · see citing works
Grangeon, M., Tomasini, P., Chaleat, S., Jeanson, A., Souquet-Bressand, M., Khobta, N., Bermudez, J., Trigui, Y., Greillier, L., Blanchon, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.002 · Cited by 202 · see citing works
Gettinger, S. N., Choi, J., Mani, N. L., Sanmamed, M. F., Datar, I. J., Sowell, R., Du, V. Y., Kaftan, E. J., Goldberg, S. B., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 186 · see citing works
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 178 · see citing works
Yoest, J. M. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 175 · see citing works
Comprehensive screening for PD-L1 expression in thyroid cancer
Ahn, S., Kim, T. H., Kim, S. W., Ki, C., Jang, H. W., Kim, J. S., Kim, H. J., Choe, J., Shin, J. H., Hahn, S. Y., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0421 · Cited by 174 · see citing works
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142 · see citing works
The intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 142 · see citing works
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0579-z · Cited by 140 · see citing works
Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1375642 · Cited by 123 · see citing works
Choueiri, T. K., Powles, T. B., Burotto, M., Bourlon, M. T., Żurawski, B. A., Oyervides-Juárez, V. M., Hsieh, J. J.-D., Basso, U., Shah, A. Y., Suárez, C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2257 · Cited by 116 · see citing works
Tray, N., Weber, J. S., & Adams, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0214 · Cited by 101 · see citing works
Ishihara, H., Takagi, T., Kondo, T., Homma, C., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.003 · Cited by 91 · see citing works
Giorgi, U. D., Cartenì, G., Giannarelli, D., Basso, U., Galli, L., Cortesi, E., Caserta, C., Pignata, S., Sabbatini, R., Bearz, A., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14461 · Cited by 83 · see citing works
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
Suo, A., Chan, Y., Beaulieu, C., Kong, S., Cheung, W. Y., Monzon, J. G., Smylie, M., Walker, J., Morris, D., & Cheng, T. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0674 · Cited by 83 · see citing works
Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J., Guimbaud, R., Meyer, N., Mazières, J., & Alric, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682383 · Cited by 47 · see citing works
Wu, C., Yang, C., Peng, M., Huang, P., Chang, C., Yeh, K., Chen, C., Wang, C., Hsu, C., Chen, I., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07508-7 · Cited by 42 · see citing works
Autoimmune Thyroid Disease Elicited by NY-ESO-1 Vaccination
Vita, R., Guarneri, F., Agah, R., & Benvenga, S. (2013) · Thyroid · doi:10.1089/thy.2013.0170 · Cited by 29 · see citing works
Bouhlel, L., Doyen, J., Chamorey, E., Poudenx, M., Ilié, M., Gal, J., Guigay, J., Benzaquen, J., Marquette, C., Berthet, J., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.019 · Cited by 26 · see citing works
Vitale, M. G., Scagliarini, S., Galli, L., Pignata, S., Re, G. L., Berruti, A., Defferrari, C., Spada, M., Masini, C., Santini, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199642 · Cited by 24 · see citing works
Kobayashi, K., Iikura, Y., Hiraide, M., Yokokawa, T., Aoyama, T., Shikibu, S., Hashimoto, K., Suzuki, K., Sato, H., Sugiyama, E., et al. (2020) · In Vivo · doi:10.21873/invivo.12083 · Cited by 20 · see citing works
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review
Ornstein, M. C., & Garcia, J. A. (2017) · Kidney Cancer · doi:10.3233/kca-170017 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
Cheung, Y.-M. M., Wang, W., McGregor, B. A., & Hamnvik, O. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03128-7 · Cited by 101 · see citing works
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 89 · see citing works
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
Du, Y., Wu, W., Chen, M., Dong, Z., & Wang, F. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.3003 · Cited by 54 · see citing works
Systemic Sclerosis Association with Malignancy
Lepri, G., Catalano, M., Bellando-Randone, S., Pillozzi, S., Giommoni, E., Giorgione, R., Botteri, C., Matucci‐Cerinic, M., Antonuzzo, L., & Guiducci, S. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08930-4 · Cited by 53 · see citing works
Self-citationFernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 47 · see citing works
Martini, D. J., Goyal, S., Liu, Y., Evans, S. T., Olsen, T. A., Case, K. B., Magod, B. L., Brown, J. T., Yantorni, L. B., Russler, G. A., et al. (2021) · The Oncologist · doi:10.1002/onco.13868 · Cited by 43 · see citing works
Baker, M. L., Yamamoto, Y., Perazella, M. A., Dizman, N., Shirali, A. C., Hafez, N., Weinstein, J. N., Simonov, M., Testani, J. M., Kluger, H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004421 · Cited by 42 · see citing works
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Gao, Y., Wu, C., Chen, X., Ma, L., Zhang, X., Chen, J., Liao, X., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049043 · Cited by 36 · see citing works
Liao, G., Wang, P., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720125 · Cited by 34 · see citing works
Paderi, A., Gambale, E., Botteri, C., Giorgione, R., Lavacchi, D., Brugia, M., Mazzoni, F., Giommoni, E., Bormioli, S., Amedei, A., et al. (2021) · Molecules · doi:10.3390/molecules26195789 · Cited by 34 · see citing works
Self-citationGiommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 29 · see citing works
Self-citationZhang, Y., Chen, J., Liu, H., Dai, J., Zhao, J., Zhu, S., Zhang, X., Liang, J., Hu, X., Zhao, J., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102787 · Cited by 27 · see citing works
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28 · see citing works
Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Hyodo, Y., Kagawa, M., Izumi, K., Oyama, M., Kawakami, S., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02406-x · Cited by 27 · see citing works
Lau, G. K. K., Sangro, B., Cheng, A., Kudo, M., Kelley, R. K., Tak, W. Y., Gasbarrini, A., Reig, M., Lim, H. Y., Tougeron, D., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001385 · Cited by 21 · see citing works
Lei, Y., Zheng, X., Huang, Q., Li, X., Qiu, M., & Liu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.914928 · Cited by 17 · see citing works
Qin, W., Yang, L., Fan, B., Zou, B., Duan, Y., Li, B., & Wang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931429 · Cited by 17 · see citing works
Quan, L., Liu, J., Wang, Y., Yang, F., Yang, Z., Ju, J., Shuai, Y., Wei, T., Yue, J., Wang, X., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2410557 · Cited by 16 · see citing works
Kerepesi, C., Abushukair, H. M., Ricciuti, B., Nassar, A. H., Adib, E., Alessi, J. V., Pecci, F., Rakaee, M., Fadlullah, M. Z. H., Tőkés, A.-M., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00439 · Cited by 15 · see citing works
Ueda, K., Suekane, S., Kurose, H., Ito, N., Ogasawara, N., Hiroshige, T., Chikui, K., Ejima, K., Uemura, K., Nakiri, M., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac009 · Cited by 14 · see citing works
Hino, C., Nishino, K., Pham, B., Jeon, W. J., Nguyen, M., & Cao, H. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993622 · Cited by 14 · see citing works
Han, X., Chen, Y., Xie, H. Y., Zhang, Y., Cui, Y., Guan, Y., Nie, W., Xie, Q., Li, J., Wang, B., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13566-6 · Cited by 13 · see citing works
Kankkunen, E., Penttilä, P., Peltola, K. J., & Bono, P. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2104132 · Cited by 13 · see citing works
Li, W., Mei, M., Liu, T., Zhang, S., Wang, Z., Suo, Y., Wang, S., Liu, Y., Zhang, N., & Lu, W. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s347163 · Cited by 12 · see citing works
Silberg, M., Krabbe, L., Bögemann, M., Schrader, A. J., Tully, K. H., & Schlack, K. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102164 · Cited by 12 · see citing works
Pacholczak‐Madej, R., Drobniak, A., Stokłosa, Ł., Bidas, A., Dobrzańska, J., Grela-Wojewoda, A., Roman, A., Tusień-Małecka, D., Walocha, J. A., Blecharz, P., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13192-8 · Cited by 12 · see citing works
Shen, K., & Liu, T. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s325467 · Cited by 12 · see citing works
Ueda, K., Ogasawara, N., Ito, N., Ohnishi, S., Suekane, H., Kurose, H., Hiroshige, T., Chikui, K., Uemura, K., Nishihara, K., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062417 · Cited by 11 · see citing works
Olsson-Brown, A. C., Jain, A., Frazer, R. D., Farrugia, D., Carser, J., Houghton, J. B., Lewis, R. D., D'Mello, S., & Emanuel, G. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00349-z · Cited by 10 · see citing works
Robesti, D., Nocera, L., Belladelli, F., Schultz, J. G., Fallara, G., Marandino, L., Raggi, D., Montorsi, F., Msaouel, P., Necchi, A., et al. (2023) · British Journal of Urology · doi:10.1111/bju.16121 · Cited by 9 · see citing works
Uemura, H., Shinohara, N., Tomita, Y., Nonomura, N., Yamada, T., Yoshida, A., & Komoto, A. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad034 · Cited by 8 · see citing works
Nukaya, T., Takahara, K., Yoshizawa, A., Saruta, M., Yano, Y., Ohno, T., Uchimoto, T., Fukuokaya, W., Adachi, T., Yamazaki, S., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.09.007 · Cited by 8 · see citing works
Wang, Y., Xiong, C., Yu, W., Zhou, M., Shugg, T., Hsu, F., Eadon, M. T., Su, J., & Song, Q. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115114 · Cited by 7 · see citing works
Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma
Sagie, S., Gadot, M., Levartovsky, M., Sorotsky, H. G., Berger, R., Sarfaty, M., & Percik, R. (2022) · Cancers · doi:10.3390/cancers14040875 · Cited by 6 · see citing works
Lu, Y., Li, Q., Xu, L., Sun, Y., Zheng, Y., Wang, Y., Liu, Y., Zhang, R., Liao, L., & Dong, J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05364-z · Cited by 6 · see citing works
Immune checkpoint inhibitors and kidney disease
Wang, Q., Moledina, D. G., & Sise, M. E. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000805 · Cited by 6 · see citing works
Gupta, M., Wells, C., Regan, M. M., Xie, W., Navani, V., Saliby, R. M., Basappa, N. S., Donskov, F. N., Yuasa, T., Takemura, K. N., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.12.011 · Cited by 6 · see citing works
Zhang, L., & Gao, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1689519 · Cited by 5 · see citing works
Roy, A. M., & George, S. (2023) · Immunotherapy · doi:10.2217/imt-2023-0010 · Cited by 5 · see citing works
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
Hammerstad, S. S., Lee, H. J., Tomer, Y., & Stefan–Lifshitz, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02608-2 · Cited by 4 · see citing works
On-treatment risk model for predicting treatment response in advanced renal cell carcinoma
Güer, M., Janitzky, A., & Schostak, M. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04545-2 · Cited by 4 · see citing works
Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
Ornelas, M., Borges‐Canha, M., Gouveia, P., Ferreira, M., Resende, E., Sá, M., & Abreu, S. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000654 · Cited by 3 · see citing works
Wang, H., Xia, J., Yü, A., Cao, M., Yang, Z., Qin, X., Liu, W., Han, Z., & Jiang, G. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206350978241105080452 · Cited by 3 · see citing works
Inoue, Y., & Inui, N. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4654-24 · Cited by 3 · see citing works
Rudzińska, A., Juchaniuk, P., Oberda, J., Krukowska, K., Krzyśkowska, S., Kuchta, E., Rodzajewska, A., Janiszewska, M., Machulska-Ciuraj, K., & Szklener, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1527103 · Cited by 2 · see citing works
Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
Xiao, M., Qian, L., Zhao, Q., Ma, J., Li, Q., Liu, Q., & Bi, Z. (2025) · Oncology Letters · doi:10.3892/ol.2025.15110 · Cited by 2 · see citing works
Enoki, M., Yamanaka, K., Kawashima, A., Fukuhara, S., & Nonomura, N. (2025) · Cureus · doi:10.7759/cureus.99745 · Cited by 1 · see citing works
Effectiveness and safety of first-line nivolumab–ipilimumab in metastatic renal cell carcinoma
Gómez, M. E., Cabetas, M. G.-T., Muñoz, C. H., Abad, M. G. C., Ferrández, L. S.-R., & Ambrosio, A. H. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261441841 · Cited by 1 · see citing works
Kobatake, K., Goto, K., Fujita, A., Babasaki, T., Ueno, T., Kurimura, Y., Fukuoka, K., Kirishima, F., Nishida, K., Hayashi, T., et al. (2026) · International Journal of Urology · doi:10.1111/iju.70461 · Cited by 1 · see citing works
YAMAGUCHI, A., Saito, Y., Okamoto, K., Furugen, A., Narumi, K., Takekuma, Y., Sakakibara‐Konishi, J., Shimizu, Y., Kinoshita, I., Sugawara, M., et al. (2024) · In Vivo · doi:10.21873/invivo.13770 · Cited by 1 · see citing works
Lei, Y., Zheng, X., Huang, Q., Li, X., Qiu, M., & Liu, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1192888/v1
(2021) · Reactions Weekly · doi:10.1007/s40278-021-02194-5
Authors, V. (2013) · Current Oncology · doi:10.3747/co.20.1906
Updating Clear Cell Renal Cell Carcinoma (a Tribute to Prof. Ondrej Hes)
Manini, C., & Lopez, J. I. (2022) · Cancers · doi:10.3390/cancers14163990
Immunbedingte Toxizitäten behandeln
Rodler, S., Tamalunas, A. J., Schulz, G. B., Apfelbeck, M., Götz, M., Berg, E. K., Stief, C. G., & Casuscelli, J. (2022) · Uro-News · doi:10.1007/s00092-022-5501-1
Wei, Y., Hong, Y., Zhou, X., Wang, H., Zhao, R., & Ma, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2749138/v1
Волкова, М. И., Nersesova, T. A., Lyadova, M. A., Kuzmina, E., Antonova, T. G., Царева, Е. В., Стативко, О. А., Черняев, В. А., & Покатаев, И. А. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-050
Varlamova, S. E., Корчажкина, Н. Б., Mochalova, A. S., & Грушина, Т. И. (2026) · Fizioterapevt (Physiotherapist) · doi:10.33920/med-14-2601-03
Genomics-Driven Immunotherapy: Advancing Cancer Treatment through Personalized Approaches
Kate, A. A., Desai, S. A., Sapkal, S. P., More, M. J., & Patel, V. P. (2026) · Current Genomics · doi:10.2174/0113892029403241260416110923
Cassaniti, M., Carrozza, F., Scodes, S., Vittimberga, I., & Tamberi, S. (2026) · Complications · doi:10.3390/complications3020012
Varlamova, S. E., Корчажкина, Н. Б., Mochalova, A. S., & Грушина, Т. И. (2026) · Fizioterapevt (Physiotherapist) · doi:10.33920/med-14-2603-04
- Authors
- Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Antonuzzo, Lorenzo
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-02-18
- Volume
- 13
- Issue
- 4
- Pages
- 860
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7922597
- OpenAlex
- W3130288202
- Cited by
- 62
- References
- 47
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 12 · 2022: 17 · 2021: 6 · 2013: 1
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Regione Toscana
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, metastatic renal cell carcinoma, nivolumab, ipilimumab, thyroid dysfunction, skin reactions, progression-free survival, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related nephritis, immune-related dermatitis, immune-related hypophysitis, immune-related colitis, immune-related encephalitis, immune-related myocarditis, immune-related hypothyroidism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
